CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01542736
NCT01542736Phase 2Completed
CompareCT.gov

Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET

University of Colorado, Denver·interventional·Posted Mar 2, 2012·Updated Jan 11, 2022

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Vincristine, and 1 other intervention for Metastatic Medulloblastoma and 2 related conditions. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2012
Enrollment StartMay 1, 2007
Primary CompletionSep 1, 2020
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 14.3 years ago

Interventions

Carboplatindrug

Administered concurrently with craniospinal radiation.

Vincristinedrug

Administered concurrently with craniospinal radiation.

24 Gyradiation

Craniospinal radiation.